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Abstract 
Dextrans are a class of carbohydrate polymers extensively applied in pharmaceutical applications, 
particularly as drug conjugate macromolecular carriers or drug delivery systems. These 
polysaccharides enable the stability of the therapeutics to be improved and for them to be delivered 
in a controlled manner, via either the parenteral and oral routes. In the latter case, due to their gel 
forming ability they may have potential as hydrophilic matrix tablets for sustained drug release.  
In this paper, we investigated the behaviour of different molecular weight (1, 40, 500 and 2300 
kDa) dextrans as tabletting excipients. Powder particle size and hygroscopic studies have been 
reported, together with tabletability, tablet stability and tablet swelling. Moreover we use tramadol 
as model compound to evaluate the ability of dextrans to control drug dissolution. The results 
suggest that dextrans with lower molecular weights may be a promising excipient to be used as 
filler for immediate release tablets, due to their good tabletability and fast dissolution rate, while 
dextrans with higher molecular weights could be an efficient disintegrant due to their swelling 
ability.  
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1. Introduction 
Dextrans are a family of high-molecular-weight polymers composed of D-glucose units inter-
connected with α-1,6 linkages, with a variable degree of side branches via α-1,2, α-1,3, or α -1,4 
linkages. In most cases the length of the side chains is short, and branched residues vary between 5-
33 %. Commercial dextrans are about 95 % α-1,6 linked and 5 % α-1,3linked [1].  
Dextrans are biosynthesised from sucrose by several species of bacteria (e.g. Leuconostoc and 
Streptococcus), through the use of specific enzymes like glucansucrases [2]. Their physicochemical 
properties are mainly related to molecular weight (Mw) and degree of branching, which in turn 
depend on the source of production [3]. 
In the last few decades dextrans have been mainly used as plasma volume expanders [2, 3]. 
However recently, dextrans have shown the potential to be used in several drug and gene delivery 
systems [4-6]. Therapeutics have been formulated as polymer-drug conjugates or in the form of 
hydrogels or particulate drug delivery systems [3, 6-10]. Fülöp et al. [11] described the use of 
cyclodextrins (β type) grafted dextrans to solubilize hydrocortisone. Dextrans have been also 
evaluated for the preparation of targeting carrier systems particularly to deliver the drug into the 
colon [12-15]. A further application of this class of polysaccharides is their use as oral tablet 
excipient. A commercial tablet formulation based on Limaprost (e.g. Opalmon®), an alprostadil 
(prostaglandin E1) analogue, employing dextran (40 kDa) and dextrin as excipients, has been 
marketed in Japan. A series of studies demonstrated how the presence of the carbohydrates could 
improve the stability of the Limaprost under high levels of humidity [16-18].  
Moreover, dextrans have been extensively utilized as controlled release polymer excipients in the 
preparation of oral hydrophilic matrix tablets [19-23]. 
Korner et al. [23], compared dextrans (Mw 70, 500 and 2000 kDa) to polyethylene oxides (PEOs) 
and hydroxypropyl methylcelluloses (HMPCs), analyzing the release and swelling mechanisms in 
correlation with the intrinsic viscosity (which in this case is an indirect measure of molecular 
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weight) of the polymer. Gil and co-workers (2006, 2007 and 2008) showed the potential of medium 
molecular weight dextrans (40-170 kDa) for immediate release, whilst the higher molecular weight 
(more than 2000 kDa) was more suitable in the formulation of extended drug release tablets. 
Based on these promising results, it has been decided to integrate the knowledge concerning the use 
of dextrans as excipients in the formulation of matrix tablets, taking into account the mechanical 
properties of the powders and how they are affected by the production speed and storage conditions.  
Dextrans with different molecular weights (1, 40, 500 and 2300 kDa) were selected from within 
those approved for pharmaceutical use, with the only exception of that of the highest molecular 
weight, which is at this time only approved as a food ingredient.  
All the dextrans were characterized in terms of their powder properties and tabletability. Moreover, 
their ability to act as controlled release agents was evaluated through dissolution studies, using 
hydroxypropyl methylcellulose (4000 cps), a common polymer used in controlled release systems, 
as reference material. The dissolution profiles, using tramadol as model drug, were explained in 
terms of the swelling ability of the formulated tablets. 
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2. Materials and methods 
2.1. Materials 
Dextrans with molecular weight of 1 kDa (Dextran 1 EP), 40 kDa (Dextran 40 EP) and 500 kDa 
(Dextran 500 pharmaceutical quality) were provided by Pharmacosmos A/S (Holbaek, DK), while a 
dextran of 2300 kDa was supplied by BIOerg srl (Jesi, IT). Hydroxypropyl methylcellulose 4000 
cps (Methocel K4M) was provided by Colorcon (Dartford, UK). Microcrystalline cellulose (Avicel 
PH 101) was provided by FMC BioPolymers (Brussels, BE) and tramadol hydrochloride was 
generously donated by the company Janssen-Cilag SpA (Borgo San Michele, IT). All the others 
materials were reagents of standard grade and were supplied by Sigma-Aldrich (St. Louis, USA). 
Throughout the text the material names will be reported with the following abbreviations: D_1kDa, 
D_40kDa, D_500kDa and D_2300kDa for dextrans with molecular weight of 1, 40, 500 and 2300 
kDa, respectively and HPMC and MCC for hydroxypropyl methylcellulose 4000 and 
microcrystalline cellulose. Molecular weight of the D_1kDa, D_40kDa and D_500kDa were 
provided by the manufacturer, while for the D_2300kDa was determined using size exclusion 
chromatography coupled to multi-angle light scattering (SEC-MALS), as described in the 
supplementary material SMT_1. 
 
2.2 Particle size analysis 
All the dextran powders were analyzed using optical microscopy (MT9000 Polarizing Microscope, 
Meiji Techno Co Ltd, JP) equipped with a 3 megapixel CMOS camera (Invenio 3S, DeltaPix, DK). 
The acquired images (2048 x 1536 pixels) were analyzed through the use of image analysis 
software (Image Pro Plus, MediaCybernetics Inc., USA), previously calibrated using a specific 
glass slide with a 5 mm graticule (S2-StageMic, Graticules Ltd, UK). One hundred particles, 
randomly selected, were analyzed in terms of projected area equivalent diameter. The obtained data 
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were analysed using the software Minitab 15 (Minitab Inc., State College, USA), in order to 
measure the most representative parameters of particles size distributions.  
 
2.3 Density and flowability 
The bulk (ρb) and tapped (ρt) densities of the samples were determined by pouring a pre-weighted 
amount of sample in a cylinder and measuring the volume occupied initially and after 300 taps 
respectively (after 200 taps the powder volume remained constant).  
Carr’s index was estimated from the bulk and tap densities according to equation 1.  
100t b
t
CI ρ ρρ−= ⋅              Equation 1 
Bulk and tapped densities were determined in triplicate. 
 
2.3 Hygroscopicity 
Dextran hygroscopicities were determined by leaving the samples at ambient conditions and 
measuring water content at predetermined time intervals using a moisture analyzer (SMO 01, 
Scaltec, DE) 
When the stable moisture content was reached, the powders were placed in a desiccator containing 
calcium chloride and the water content was monitored as previously described in the tests at 
ambient conditions. 
The temperature and the moisture percentage were monitored twice a day during both experiments, 
giving the following average conditions:  
 
(i) 18.4 ± 0.6 °C and 67.5 ± 3.8 % during the experiments performed at ambient conditions; 
(ii) 20.7 ± 1.1 °C and 6.1 ± 1.4 % during the experiments performed inside the dessicator. 
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The tests were also performed on two control polysaccharides, MCC and HPMC. MCC was 
selected as example of a direct compression excipient while HPMC as controlling release excipient. 
 
2.4 Tabletability 
Dextran tablets were prepared using a fully instrumented 10 station rotary tablet press (Ronchi, IT). 
Details of mounted traducers and their calibration have been previously reported [24, 25]. The 
tableting machine was equipped with 6 mm diameter, round, flat-faced punches. The tabletability of 
the original dextrans was evaluated by preparing for each sample 10 batches of 100 mg tablets at 
different pressures, 50, 100, 150, 200 and 250 MPa and at two speeds, 5 and 30 rpm. For each 
batch, 10 tablets were analyzed using a hardness tester (TBH30, Erweka, DE) and the obtained 
crushing forces (H) were converted into tensile strength (TS) using  the following equation: 
tD
HTS ⋅⋅⋅= π2                                     Equation 1 
Where D is the tablet diameter and t the tablet thickness, measured using a micrometer (103-137, 
Mitutoyo, Japan). 
The analyses were repeated also for the samples left under ambient conditions for the appropriate 
times necessary to reach stable moisture contents. The hardness of each batch was determined by 
measuring 10 tablets.  
 
2.5 Tablet stability 
Dextran matrices were prepared by setting the punch penetration in order to produce 100 mg tablets 
at a pressure of 200 MPa. The tablets were left at ambient conditions for 5 weeks (average 
temperature and moisture were 20.3 ± 1.2 °C and 65.2 ± 2.6 %) during which time the variation in 
weight and hardness were monitored. For each time point 5 tablets were analyzed.  
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In this analysis, the hardness values were not transformed in tensile strength. During the monitored 
period, the tablets prepared with D_1kDa lost their regular shape making impossible the 
measurement of the diameter and thickness values necessary for the calculus of the tensile strength. 
 
2.6 Dissolution testing 
Five batches of tablets were prepared by compression of blends composed of 49.5 mg dextran 
(D_1kDa, D_40kDa, D_500kDa and D_2400kDa) or HPMC (used as control), 49.5 mg tramadol 
and 1 mg of magnesium stearate (lubricant). All tablets were characterized by the same hardness, 
equal to 30 N (effective values were 30.9 ± 2.5). 
Dissolution studies were performed at 37 ± 0.5 °C using an USP dissolution apparatus 1 (AT7 
smart, Sotax, CH) with rotation speed of 50 rpm. Potassium phosphate buffer (50 mM) pH 6.8 (700 
ml) was selected as medium according to previously reported studies concerning tramadol release 
[26, 27]. For each batch 3 tablets were tested and drug release was monitored 
spectrophotometrically at 271 nm (UV-1800, Shimadzu Corporation, JP) for a period of 4 hours. 
 
2.7 Tablet swelling 
The analysis of tablet swelling was performed using the same procedure followed by Roberts at al. 
(2007) to study HPMC matrix tablets [28]. Briefly, each tablet was placed vertically in a small glass 
Petri dish, and 10 ml of dissolution medium was added at ambient temperature. The Petri dish was 
placed on a plane surface and the digital camera was placed above. The analysis was performed on 
tablets composed of 99 % dextran (or HPMC) and 1 % of magnesium stearate, having a hardness of 
30 N. Images were obtained at 0, 5, 10, 15, 30, 45, 60 and 90 minutes. Each image was calibrated 
using a graduated ruler and analyzed with the software Image Pro Plus (MediaCybernetics Inc., 
USA). The analysis was performed in triplicate. 
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3. Results and discussion 
3.1 Particle size and flowability analysis 
Microscopic images of the different dextran powders are reported in Figure 1. They appear to be 
characterised by differently shaped fine particles, with sizes lower than 50 µm. Specifically, all the 
samples provided by Pharmacosmos, D_1kDa, D_40kKDa and D_500kDa, showed a perfect 
circular shape with a darker inner core, while the sample D_2300kDa was made up by particles of 
irregular shape. The observation of particles with smaller size and perfectly round shape suggests 
that low molecular weight dextrans were probably produced by spray drying, this is supported by 
comparison of similar images reported in the previous literature [29]. On the other hand, the 
particles images of the sample with highest molecular weight suggest that it was probably obtained 
through a milling process.  
All the images acquired were further processed using image analysis software in order to measure 
the size of each single particle and obtain the particle size distributions of the different batches. 
These results are summarized in the Figure 2 using the box plots. Although the dextran samples 
were produced using different techniques, they show very similar results. The median particle size 
ranged from a value of 15.9 µm for the D_1kDa to 22.8 µm for D_2300kDa (table 1), while the 
width of the distributions, calculated as the interquartile range, varied between 7.6  µm to 13.4 µm 
for the samples D_1kDa and D_500kDa, respectively (table 1). All the particle size distributions 
were slightly asymmetric, having the right tail longer than the left one (the values of skewness were 
in the interval 0.5 to 1.3 for all the samples). 
All the detxtran samples were characterized also in term of particles flowability using the Carr 
index. The results, reported in table 1, ranged from 20.5 to 27.7. According to the United States 
Pharmacopoeia (USP) and the European Pharmacopoeia (EP), the obtained values of Carr index 
indicate a flowability behaviour defined as “passable” (Carr index in the range 21-25) or “poor” 
(Carr index in the range 26-31). Such behaviour is related to the low values of particles size. Carr 
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index results reported in the literature for samples having a particle size in the range of around 10-
20 µm and obtained troughs spray drying are in the range 18-48 [30, 31], comparable with the 
values found for dextran samples. 
 
3.2 Hygroscopicity 
The ability to take up water from the environment is a central attribute of any powdered material 
that strongly influences its storage and handling conditions. The water bound to the hydrophilic 
groups of a substance acts as a plasticizer and can markedly change its properties (e.g. tabletability, 
flowability and stability) [32, 33].  
All polymeric materials with a high number of hydrophilic groups along their backbone, whilst 
being glassy or possessing glassy regions (e.g. dextrans), are able to adsorb high amounts of water 
and consequently change their physical properties [32, 34].  
The kinetics of water absorption and desorption when the powders were stored at ambient and dry 
conditions are reported in Figure 3A and Figure 3B respectively. The dextran samples showed 
different initial moistures; the powders with the lower molecular weights, i.e. those below 500 kDa, 
had moisture contents in the range of 6-7 %, while the remaining sample, the 2300 kDa, had a 
moisture content of approximately 10 %. All the dextrans quickly absorbed environmental water, 
reaching a stable moisture value in 2-4 days (Figure 3A). The amount of water sorbed is apparently 
dependent upon the polymer molecular weight; where materials with a lower Mw show the higher 
amount of moisture content. The only exception is the dextran 1_kDa.  
This result can be explained by observing the images (supplementary material SF1) of all the 
materials analysed at the start of the test and then after 8 days. All the dextrans remain in the 
powder form during their exposure at ambient conditions, with the only exception being the 1_kDa. 
This sample becomes a “rubbery block” as it absorbs water. In this condition, the moisture analyser 
was not be able to accurately determinate the weight loss since the water is more strongly bound. 
The change of the powder 1_kDa into a block makes it virtually useless for the preparation of solid 
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dosage forms. Thus for dextrans of lower molecular weight the storage and handling conditions 
have to be rigorously controlled.  
Water absorption was revealed to be a reversible phenomenon, as is evident from Figure 3B. When 
the samples were stored at around 6 % environmental humidity, they slowly released the absorbed 
water (most of the samples returned back at the initial moisture values after 15 days). All the 
samples had a similar behaviour, with water desorption curves almost overlapping. The sample 
1_kDa always remained as a “block”. However, its consistency changed from rubbery to rigid and 
friable.  
The control materials showed similar absorption kinetics than dextrans, even if the total amount of 
absorbed moisture was lower. Also in this case, the process appeared to be reversible when the 
samples was stored at dry conditions.  
 
3.3 Tabletability and tablets stability. 
Tabletability is one the most relevant features of excipients intended for the preparation of 
pharmaceutical solid dosage forms. It represents the ability of a material in powder form to produce 
tablets with good mechanical properties.  
In this work, all the dextrans were characterized in terms of tabletability highlighting the effect of 
molecular weight, compaction speed and moisture absorbed. These results are summarized in 
Figure 4.  
In Figure 4A the curves of the samples with the initial moisture content (the values at time zero in 
Figure 3A) are reported. Dextrans showed good tabletability, being able to produce tablets with 
tensile strength in the range 5-12 MPa when compressed at 200 MPa. Such results suggest that 
dextrans have a tabletability almost comparable with that of microcrystalline cellulose and much 
higher than many other pharmaceutical excipients used as diluents or controlled release polymers in 
the direct compression process [35, 36]. There is no apparent trend taking into account the 
molecular weights. Samples with a weight of 40 kDa and 500 kDa had the higher tabletability. It is 
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interesting to observe that up to 100 MPa, all the samples have the same behaviour, with data 
almost overlapped, while it is only at higher pressure that polymers with different Mw begin to show 
a variable tabletability. There is no effect of production speed, with the exception of the 
D_2300kDa. Such a difference is most probably due to the different moisture content (10 % versus 
6-7 % for the others polymers), as previously discussed. Figure 4B presents the tabletability of the 
samples exposed at ambient conditions for 8 days (they have a moisture content as defined at the 
time point “8 days” in Figure 3A). There is no data for the sample D_1kDa since it was no longer 
in a suitable state to be loaded into the rotary tableting instrument. At higher moisture content 
dextran powders were more tabletable, but only at the lower compaction pressure (50-100 MPa). 
Moreover, also the production speed begins to affect the tablet behaviour. In fact, the tablets 
produced at the lower speed are slightly harder, even if only at the higher compaction pressure 
applied. These results are not unexpected; water acts as plasticizer increasing the material’s 
viscoelasticity. This results in higher ductility (better tabletability) and also more strain rate 
sensitivity (higher tabletability at low production speed) [37-39]. These results show that dextran 
powders are characterized by a certain hygroscopicity, which affects their compaction behaviour.  
The next step is to verify whether the environmental conditions have a similar effect on the 
mechanical properties of dextran tablets, which were produced with the polymer “as received” and 
then stored at ambient conditions. The test was only performed on the sample D_1kDa, since this 
material was more sensitive to the absorbed moisture and to the D_500kDa sample, which was used 
as a “typical” dextran as it had a comparable behaviour to that of all the other dextrans.  
The amount of sorbed moisture, expressed as variation of tablet weight, and the tablet hardness are 
reported in Figure 5. Tablets prepared with the two dextrans, D_1kDa and D_500kDa, showed 
almost superimposed weight increase profiles, with about 6 % water absorbed during the 35 days of 
the test. These results are consistent with those reported in the hygroscopicity section. However, the 
results in terms of tablet hardness were completely different. The D_500kDa tablets had a constant 
value of hardness for the first 15 days with a remarkable increase in the following week, which has 
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been kept constant up to the end of experiment. On the other hand, D_1kDa tablets had a 
completely different behaviour; their hardness constantly decreased during the experiment time and 
was detectable only for the first 15 days (the hardness of D_500kDa tablets has been easily 
monitored for the whole duration of the experiment). After this period, the D_1kDa tablets turned 
into a “plastic” mass, which deformed instead of breaking during the hardness measurement. The 
images of the tablets during the 35 days of the test clearly show how it is strong the effect of 
moisture on D_1kDa tablets (Figure SF2 on supplementary materials).  
 
3.4 Dissolution testing 
To evaluate the ability of dextrans to work as controlled release excipients, matrices containing 
tramadol hydrochloride as model drug were prepared with the four different dextrans and with 
HPMC K4M as model controlled release polymer.  
Dissolution profiles and dissolution rate traces are shown in Figures 6A and B, respectively. 
Dextran controls the drug dissolution as a function of their molecular weight, with the 50 % of 
tramadol released at 3, 6.5, 9 and 42 minutes for the D_1kDa, D_40kDa, D_500kDa and 
D_2300kDa, respectively.  
In any case, their ability to prolong drug dissolution was less effective than HPMC. The sample 
D_2300kDa provided an anomalous dissolution profile; the release of the drug was very slow and 
superimposable to that of HPMC matrices during the first 30 minutes and then accelerates to finish 
after 2 hours. This aspect is clearly visible analysing the dissolution rates (Figure 6B). All the 
samples, including HPMC, have a maximum dissolution rate at 5 minutes and then the process 
slows down up to a rate of zero in a time dependent manner for each polymer type. The only 
exception is the sample D_2300kDa, which show 2 peaks in the dissolution rate profiles, one at 5 
minutes and the other at 45 minutes.  
 
3.5 Tablets swelling  
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To explain the results obtained during the dissolution studies, all the tablets were tested in terms of 
the variation of their axial and radial dimensions. Percent normalised size variation was calculated 
as the axial or radial length increase/decrease with respect to the initial value.  
Results (Figure 7) showed marked differences in the swelling behaviour of the tablets as a function 
of dextran molecular weight both in the axial and radial direction. The main behaviour of the 
polymers moves from a completely erosive mechanism for the D_1kDa to an almost predominantly 
swelling mechanism for the D_2300kDa.  
In the first case, the tablets dissolve in less than 20 minutes while in the latter there is a size increase 
of more than double with respect to the initial dimensions. The polymers with a molecular weight of 
40 kDa and 500 kDa show an intermediate behaviour. In the Figure 7, all the traces end at different 
times without reaching the -100 value (tablet dissolved). This is due to the breakage of tablets in to 
pieces, which made it impossible to measurement the size increase. For sample D_500kDa and 
especially D_2300kDa, after a certain time, the tablets lost their rectangular shape and consequently 
the parameters reported in Figure 7 are only an estimation (in the traces of Figure 7 a dotted line 
indicates the estimated values, while the solid line the value correctly measured). The differences in 
the swelling ability of the different materials are clearly evident observing Figure 8, where the 
images of all the tablets are compared during the first 30 minutes of the test.  
Swelling results appear to be related with the thickening ability of the different dextrans, as reported 
in the supplementary materials SMT_2. Thus, a purely erosive behaviour is observed with the only 
polymer having a virtually zero thickening power while the degree of swelling is associated with a 
particular dextran’s ability to build up viscosity.  
It is interesting to note as there is correlation between the dissolution profiles and the swelling data 
of the D_2300kDa. This sample, showed an increase of the drug release in the time range 30 and 60 
minutes, which correspond to the time interval where the sample completely lost its regular shape 
(30 minutes) and break into pieces (60 minutes) during the swelling analysis. A completely 
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irregular swollen tablet has a surface area much higher and consequently the drug is quickly 
released. 
These results also allow an easy comparison between dextrans and HPMC. Dextrans suddenly swell 
or erode ending up to dissolve completely or break into pieces in less than 1 hour, while HPMC 
shows a constant and regular swelling which takes place during the entire duration of test. This 
difference can be attributed to the different properties of the gelled layer around the tablets and 
consequently to the thickening ability of the polymers (SMT_2). As the thickening power of the 
polymers decrease, the gelled layer around the tablets will be less compact, allowing an easier water 
diffusion, faster polymers hydration and dissolution. 
The data obtained analysing the axial swelling was qualitatively similar to those of the radial 
swelling. The only difference was in the absolute values of normalized size increase. In the axial 
parameters, for each time point the swelling was roughly the double respect to those measured in 
the radial direction. Such a result is consistent with the previously published paper on HPMC 
swelling [28, 40, 41].  
 
4. Conclusions  
Dextrans of molecular weights in the range of 1 kDa to 2300 kDa were tested in terms of their 
ability to produce tablets and to control tramadol release. All dextrans showed good tabletability, 
almost comparable with that of microcrystalline cellulose and much higher than many other 
pharmaceutical excipients. However, their use as controlled release polymer for the preparation of 
matrix tablets does not appear particularly promising. Dextran polymeric chains showed fast 
hydration kinetics with high amount of water absorbed, which turned into fast dissolution or fast 
swelling as a function of the molecular weight. 
Nevertheless, these results suggest other uses for dextrans in tablet formulation both in 
pharmaceutical and nutraceutical products. Specifically, the sample with lowest molecular weight is 
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a very promising candidate to be used as filler for immediate release tablets, thanks to its good 
tabletability and fast dissolution rate, while the sample with highest molecular weight could be an 
efficient disintegrant due to its swelling ability.  
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Table 1: Density, flowability and particle size of dextran samples. 
Sample 
Bulk density 
(g/cm3) 
Tap density 
(g/cm3) 
Carr index D50 (µm)/ IQR (µm)a 
D_1kDa 0.47±0.00 0.61±0.00 22.89±0.00 15.92 / 7.64 
D_40kDa 0.40±0.01 0.53±0.01 25.00±0.42 21.64 / 11.46 
D_500kDa 0.41±0.02 0.57±0.00 27.74±3.88 21.66 / 13.38 
D_2300kDa 0.53±0.00 0.67±0.01 20.49±0.69 22.78 / 13.32 
a
 D50 represents the median diameter and IQR the interquartile range 
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Figures and table captions 
 
Figure 1: Optical microscope images of dextrans. 
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Figure 2: Box plot of the particle size distributions of the dextran powders. In the box plot the box 
horizontal borders represent the 25th and 75th percentile, the horizontal lines in the middle of the box 
represents the median value, the black circle the mean value and the two whiskers the 5th and 95th 
percentile respectively.  
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Figure 3: Variation of moisture content of dextrans and control material when exposed at A) 
ambient conditions (18.4±0.6 °C and 67.5±3.8 % UR) and at B) dry environmental conditions 
(20.7±1.1 °C and 6.1±1.4 % UR). 
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Figure 4: Tabletability curves (mean ± SD n = 10) of dextrans at a production speed of 5(open 
symbols) and 30 rpm (closed symbols) and with a moisture content equal to (A) the value of the “as 
received samples” and to (B) the value reach after 8 days of exposure to environmental conditions 
(18.4±0.6 °C and 67.5±3.8 % UR).  
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Figure 5: Variation of tablets hardness and weight during their exposure at ambient conditions 
(20.3 ± 1.2 °C and 65.2±2.6 % UR). (mean ± SD n = 5) 
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Figure 6: The effect of molecular weight on A) the release of tramadol hydrochloride B) the release 
rate of tramadol hydrochloride from dextrans matrices. HPMC is reported as control (mean ± SD n 
= 5). 
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Figure 7: The effect of molecular weight on the percent normalised axial (A) and radial (B) size 
variation for dextran matrices. HPMC is reported as control. (mean ± SD n = 3). 
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Figure 8: The effect of time on the size variation of dextran matrices at various time points (the 
units are minutes). HPMC is reported as control. 
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Figure SF1: Images of dextran powders (A) as received and (B) after 8 days of exposure to 
environmental conditions (18.4±0.6 °C and 67.5±3.8 % UR).  
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Figure SF2: Images of dextran tablets during their exposure to the environmental conditions (20.3 
± 1.2 °C and 65.2±2.6 % UR)at the different time points (the units are days).  
 
SMT_1: High performance size exclusion chromatography coupled to multi-angle light 
scattering (HPSEC-MALS) 
2 mg/mL of sample was dissolved in distilled. High performance size exclusion chromatography 
(HPSEC) was performed at room temperature on a system consisting of a PL aquagel guard column 
(Polymer Labs, Amherst, U.S.A.) followed by in series (PL aquagel-OH 60, PL aquagel-OH 50 and 
PL aquagel-OH 40) eluted with distilled water at a flow rate of 42 mL/h. The eluent was detected 
on-line by:  
 
1. DAWN EOS light scattering (LS) detector (Wyatt, Santa Barbara, U.S.A.) 
2. T-270 differential pressure viscometer (DPV) (Viscotek, Huston, U.S.A.) 
3. rEX differential refractometer (RI) (Wyatt, Santa Barbara, U.S.A.) 
 
The refractive index increment, dn/dc was taken to be 0.15 ml/g. 
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From the analysis by SEC-MALS the water-soluble portion of the dextran provided by BIOerg was 
estimated to have a weight-average molecular weight of 2.3 x 106 g/mol (2300 kDa) and a 
polydispersity (Mw/Mn) of 2.4. 
 
SMT_2: Viscosity of the dextran and HPMC solutions 
All the dextran solutions were prepared by dispersing the polymer in water under magnetic stirring, 
while the HPMC solutions were prepared through the “hot/cold” technique. Briefly, the HPMC 
powder was dispersed in 1/3 of the required amount of hot water (70°C) adding then the remaining 
amount of medium during the cooling phase at ambient temperature under magnetic stirring. All the 
solutions were left at 5°C for at least 24 hours before being analysed.  
All the solutions were prepared in different range of concentrations (% w/w) in order to take into 
account their different thickening properties and consequently obtain comparable viscosity values 
(in the range of 0-1 Pa*sec). 
Flow curves were determined with a controlled stress rheometer (Stress Tech, Reologica) by a steel 
cone–plate geometry (C40/4). Shear rate was increased from 1 to 150 sec-1 and the corresponding 
shear stress measured, at a constant temperature of 25 and 37°C.  
Each sample was tested in triplicate. 
The flow curves were then analysed to obtain the viscosity by the Power-law equation: 
nkγσ =
 
 
Where σ is the shear stress, γ  the shear rate, k the consistency index and n the power law index.  
Power law equation is an easy rheological model able to describe the flow of Newtonian and many 
non-Newtonian systems. The consistency index k, also called power law viscosity, is related to the 
system viscosity while the power law index n is related to the flow patterns. n values equal to 1 
indicate a Newtonian behaviour while values lower and higher than 1 suggest shear thinning and 
thickening behaviour respectively. 
 
The results of power law analysis are reported in the following figure SMT_2. All the analysed 
polymers showed very different thickening ability and the following rank of viscosity (power law 
viscosity) values are observed: D2300_kDa >> D500_kDa > D40_kDa >>D1_kDa. It need to be 
highlighted that the sample D1_kDa had viscosity values comparable with that of pure water and 
consequently its thickening power is virtually nil, at least in the concentration range analysed (5-
30%). The sample D2300 kDa showed definitely higher viscosity values among all the tested 
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dextrans, even if its thickening ability is not comparable with that of HPMC. In addition, all the 
samples are Newtonian except the HPMC and the D2300_kDa at the higher concentrations, where a 
pseudoplastic behaviour is observed.  
No differences were observed at the two tested temperature, 25 and 37°C. 
 
 
Figure SMT_2: Effect of polymer type, polymer concentration and temperature on the power law 
viscosity (consistency index k) and  the power law index (n) of aqueous dispersions.  
 
 
